Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ERIS

ERIS

Eris Lifesciences Limited
Small-capPharma ↗

What the six lenses say about ERIS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1324.3
2026-09-08
VWAP · 1Y anchor
₹1501
-11.8% from VWAP
P/E · TTM
29.3×
TTM EPS ₹45.1
52-week range
10%
position low→high
RSI(14)
45
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How ERIS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD313›

The actual numbers

Price vs VWAP (1y)-11.8%
EMA trend stackDown · 21<50<200
Price vs 200-EMA-6.3%
Price vs 50-EMA-2.7%
RSI(14)45
RS vs Nifty 500 · 3M-7.4%
RS vs sector · 3M-13.5%
52-week range10%
Volume vs 30d avg0.30×
Volume vs 60d avg0.35×
ATR(14) · volatility36.2
Bollinger width · vol contraction0.073
FundamentalD864›

The actual numbers

Return on equity (ROE)18.7%
Return on capital (ROCE)14.1%
Operating margin26.6%
Net margin20.7%
Revenue growth · YoY+8.2%
EPS growth · YoY+74.4%
Debt / equity0.60×

Full 8-quarter history in the financials table below.

ValuationD842›

The actual numbers

P/E (TTM)29.3×
TTM EPS₹45.1
52-week range10%
CatalystD437›

The actual numbers

Earnings & momentum38
Capital actions6
Governance94

Every filing in the corporate-announcements panel below.

FlowD958›

The actual numbers

Promoter holding53.9%
Delivery · 30d avg58.8%
Up/down-day asymmetry5.6pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D3 + D9 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
17
Conviction score 17/100 · avg-decile strength 6.0/10
Conviction score17/100›
TechnicalD3›
FundamentalD8›
ValuationD8›
CatalystD4›
FlowD9›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.7pp
+3.3pp
-0.8pp
-5.8pp
+0.1pp
-18.6pp
Nifty 500
Broad-market baseline
+0.6pp
+3.3pp
-1.8pp
-7.4pp
-5.7pp
-23.8pp
Sector
Own-sector index
—
—
-4.7pp
-13.5pp
-18.8pp
-44.6pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ERIS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1324.30+2.60

Relative strength

RS vs baseline · rebased to 100

ERIS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
91.99+0.57

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)720739727705773792807757
↳ change QoQ—+2.7%-1.6%-3.1%+9.6%+2.5%+1.9%-6.2%
EBITDA (₹cr)252269255252277288282272
EBITDA margin35.0%36.4%35.0%35.7%35.8%36.4%34.9%35.9%
PAT (₹cr)899687102125134109279
↳ change QoQ—+7.8%-9.8%+17.3%+22.5%+7.2%-18.7%+156.0%
Net margin12.4%13.0%11.9%14.5%16.2%16.9%13.5%36.9%
EPS (₹)6.116.736.156.898.668.827.3220.33
D/E————————
YoY growth · Mar '26Revenue +7.4% YoYPAT +173.5% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 9 Sep '26
    LOWgovernance
    Agreements
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 24 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    LOWgovernance
    Agreements
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jul '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Jul '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Jun '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds ERIS

Mutual funds holding ERIS (10)

FundWeightAUM ₹crGrade
HDFC Small Cap Gr2.10%41,679
HDFC Hybrid Eq Gr1.48%22,521
DSP Small Cap Reg Gr0.82%20,221
Franklin India Flexi Cap Gr0.98%19,509
HSBC Small Cap Fund Reg Gr0.59%17,784
Franklin India Small Cap Gr2.09%14,467
Mirae Asset Aggressive Hybrid Reg Gr0.56%9,536
Aditya BSL Equity Hybrid '95 Gr0.71%7,210
Franklin India ELSS Tax Saver Gr1.01%6,239
UTI Small Cap Reg Gr1.42%5,263

ETFs holding ERIS (2)

ETFWeightGrade
Mirae Asset Nifty 500 Healthcare ETF0.53%
Motilal Oswal BSE Healthcare ETF0.51%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma